JP2019519570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519570A5 JP2019519570A5 JP2018568195A JP2018568195A JP2019519570A5 JP 2019519570 A5 JP2019519570 A5 JP 2019519570A5 JP 2018568195 A JP2018568195 A JP 2018568195A JP 2018568195 A JP2018568195 A JP 2018568195A JP 2019519570 A5 JP2019519570 A5 JP 2019519570A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- concentration
- brincidofovir
- aqueous
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 74
- WXJFKKQWPMNTIM-VWLOTQADSA-N [(2s)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid Chemical compound CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)CN1C=CC(N)=NC1=O WXJFKKQWPMNTIM-VWLOTQADSA-N 0.000 claims description 39
- 229950005107 brincidofovir Drugs 0.000 claims description 39
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 26
- 229930195725 Mannitol Natural products 0.000 claims description 26
- 239000000594 mannitol Substances 0.000 claims description 26
- 235000010355 mannitol Nutrition 0.000 claims description 26
- 239000004067 bulking agent Substances 0.000 claims description 25
- 239000000872 buffer Substances 0.000 claims description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 239000008121 dextrose Substances 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 229930064664 L-arginine Natural products 0.000 claims description 16
- 235000014852 L-arginine Nutrition 0.000 claims description 16
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 14
- 230000009385 viral infection Effects 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 10
- 208000036142 Viral infection Diseases 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- 235000009697 arginine Nutrition 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000008176 lyophilized powder Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 150000005846 sugar alcohols Chemical class 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 206010018910 Haemolysis Diseases 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 2
- 241001631646 Papillomaviridae Species 0.000 claims description 2
- 241001505332 Polyomavirus sp. Species 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000008588 hemolysis Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 229960000281 trometamol Drugs 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021075612A JP7221485B2 (ja) | 2016-06-28 | 2021-04-28 | ブリンシドフォビルの製剤 |
| JP2023005643A JP7407984B2 (ja) | 2016-06-28 | 2023-01-18 | ブリンシドフォビルの製剤 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355844P | 2016-06-28 | 2016-06-28 | |
| US62/355,844 | 2016-06-28 | ||
| US201662394665P | 2016-09-14 | 2016-09-14 | |
| US62/394,665 | 2016-09-14 | ||
| US201762446213P | 2017-01-13 | 2017-01-13 | |
| US62/446,213 | 2017-01-13 | ||
| US201762465053P | 2017-02-28 | 2017-02-28 | |
| US62/465,053 | 2017-02-28 | ||
| US201762507397P | 2017-05-17 | 2017-05-17 | |
| US62/507,397 | 2017-05-17 | ||
| US201762512825P | 2017-05-31 | 2017-05-31 | |
| US62/512,825 | 2017-05-31 | ||
| PCT/US2017/039804 WO2018005676A1 (en) | 2016-06-28 | 2017-06-28 | Formulations of brincidofovir |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021075612A Division JP7221485B2 (ja) | 2016-06-28 | 2021-04-28 | ブリンシドフォビルの製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519570A JP2019519570A (ja) | 2019-07-11 |
| JP2019519570A5 true JP2019519570A5 (enExample) | 2020-02-20 |
| JP6878473B2 JP6878473B2 (ja) | 2021-05-26 |
Family
ID=59313330
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568195A Active JP6878473B2 (ja) | 2016-06-28 | 2017-06-28 | ブリンシドフォビルの製剤 |
| JP2021075612A Active JP7221485B2 (ja) | 2016-06-28 | 2021-04-28 | ブリンシドフォビルの製剤 |
| JP2023005643A Active JP7407984B2 (ja) | 2016-06-28 | 2023-01-18 | ブリンシドフォビルの製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021075612A Active JP7221485B2 (ja) | 2016-06-28 | 2021-04-28 | ブリンシドフォビルの製剤 |
| JP2023005643A Active JP7407984B2 (ja) | 2016-06-28 | 2023-01-18 | ブリンシドフォビルの製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20170368082A1 (enExample) |
| EP (2) | EP3474822B1 (enExample) |
| JP (3) | JP6878473B2 (enExample) |
| CN (4) | CN114569547A (enExample) |
| AU (2) | AU2017290703B2 (enExample) |
| DK (1) | DK3474822T3 (enExample) |
| ES (1) | ES3037596T3 (enExample) |
| FI (1) | FI3474822T3 (enExample) |
| PL (1) | PL3474822T3 (enExample) |
| PT (1) | PT3474822T (enExample) |
| WO (1) | WO2018005676A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116825C2 (uk) | 2013-11-15 | 2018-05-10 | Чимерикс Інк. | Морфологічні форми гексадецилоксипропілових складних ефірів фосфонової кислоти і способи їх синтезу |
| AU2017290703B2 (en) * | 2016-06-28 | 2023-03-30 | Emergent Biodefense Operations Lansing Llc | Formulations of brincidofovir |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| CN114073772A (zh) * | 2020-08-18 | 2022-02-22 | 上海市公共卫生临床中心 | 铁螯合剂在制备用于治疗或预防多瘤病毒感染的药物中的用途 |
| CN114558022B (zh) * | 2022-02-16 | 2023-11-17 | 华中农业大学 | 布林西多福韦在制备抗伪狂犬病毒药物中的应用 |
| CN114732821A (zh) * | 2022-04-24 | 2022-07-12 | 华中农业大学 | 西多福韦的前药在制备防治非洲猪瘟药物中的应用 |
| JP7417339B1 (ja) | 2023-08-07 | 2024-01-18 | シンバイオ製薬株式会社 | アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療 |
| AU2024353056A1 (en) * | 2023-09-29 | 2026-04-23 | Symbio Pharmaceuticals Limited | Brincidofovir for treatment of multiple sclerosis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716825B2 (en) | 1999-12-03 | 2004-04-06 | The Regents Of The University Of California | Phosphonate compounds |
| JP4136340B2 (ja) * | 2000-08-18 | 2008-08-20 | 武田薬品工業株式会社 | 注射剤 |
| JP2008538354A (ja) | 2005-04-08 | 2008-10-23 | キメリクス，インコーポレイテッド | ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法 |
| WO2006110655A2 (en) | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| CN101678122A (zh) * | 2007-04-27 | 2010-03-24 | 奇默里克斯公司 | 在核苷给药的受体中降低肾中毒性的方法 |
| JP2011116658A (ja) * | 2008-03-13 | 2011-06-16 | Chemo-Sero-Therapeutic Research Inst | 豚萎縮性鼻炎用薬剤の製造方法 |
| US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| WO2011017253A1 (en) | 2009-08-03 | 2011-02-10 | Chimerix, Inc. | Composition and methods of treating viral infections and viral induced tumors |
| AU2010313273B2 (en) | 2009-10-30 | 2015-04-02 | Emergent Biodefense Operations Lansing Llc | Methods of treating viral associated diseases |
| PT2508170E (pt) | 2009-12-03 | 2015-10-16 | Shanghai Hengrui Pharm Co Ltd | Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação |
| US20110263536A1 (en) | 2010-04-22 | 2011-10-27 | Chimerix, Inc. | Methods of Treating Orthopox Virus Infections and Associated Diseases |
| CN105998039A (zh) | 2010-08-31 | 2016-10-12 | 奇默里克斯公司 | 膦酸酯衍生物及其合成方法 |
| US20140303092A1 (en) * | 2011-10-26 | 2014-10-09 | Chimerix, Inc | Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection |
| WO2013163509A1 (en) | 2012-04-27 | 2013-10-31 | Chimerix, Inc. | A method of mitigating virus associated end-organ damage |
| UA119324C2 (uk) * | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| UA116825C2 (uk) * | 2013-11-15 | 2018-05-10 | Чимерикс Інк. | Морфологічні форми гексадецилоксипропілових складних ефірів фосфонової кислоти і способи їх синтезу |
| AU2017290703B2 (en) * | 2016-06-28 | 2023-03-30 | Emergent Biodefense Operations Lansing Llc | Formulations of brincidofovir |
-
2017
- 2017-06-28 AU AU2017290703A patent/AU2017290703B2/en active Active
- 2017-06-28 ES ES17737695T patent/ES3037596T3/es active Active
- 2017-06-28 CN CN202210134248.1A patent/CN114569547A/zh active Pending
- 2017-06-28 WO PCT/US2017/039804 patent/WO2018005676A1/en not_active Ceased
- 2017-06-28 EP EP17737695.1A patent/EP3474822B1/en active Active
- 2017-06-28 CN CN201780040478.9A patent/CN109475497A/zh active Pending
- 2017-06-28 PL PL17737695.1T patent/PL3474822T3/pl unknown
- 2017-06-28 FI FIEP17737695.1T patent/FI3474822T3/fi active
- 2017-06-28 EP EP23195544.4A patent/EP4295853B1/en active Active
- 2017-06-28 CN CN202411127002.7A patent/CN119139329A/zh active Pending
- 2017-06-28 JP JP2018568195A patent/JP6878473B2/ja active Active
- 2017-06-28 CN CN202410393564.XA patent/CN118416082A/zh active Pending
- 2017-06-28 DK DK17737695.1T patent/DK3474822T3/da active
- 2017-06-28 US US15/636,393 patent/US20170368082A1/en not_active Abandoned
- 2017-06-28 PT PT177376951T patent/PT3474822T/pt unknown
-
2019
- 2019-12-20 US US16/722,699 patent/US20200138835A1/en not_active Abandoned
-
2021
- 2021-04-28 JP JP2021075612A patent/JP7221485B2/ja active Active
-
2022
- 2022-07-25 US US17/872,921 patent/US12485131B2/en active Active
-
2023
- 2023-01-18 JP JP2023005643A patent/JP7407984B2/ja active Active
- 2023-06-28 AU AU2023204117A patent/AU2023204117B2/en active Active
-
2025
- 2025-11-04 US US19/379,308 patent/US20260151411A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chaturvedi et al. | A review on mucoadhesive polymer used in nasal drug delivery system | |
| JP2023033538A5 (enExample) | ||
| ES2543108T3 (es) | Preparación sólida fácilmente administrable | |
| FI3474822T3 (fi) | Brinsidofoviirin formulaatioita | |
| US10086064B2 (en) | Vaccine compositions | |
| RU2001108569A (ru) | Стабилизированная фармацевтическая композиция в лиофилизированной форме | |
| KR20130083376A (ko) | 비강내 전달을 위한 방법 및 조성물 | |
| JP2002363097A5 (enExample) | ||
| JP2015515968A5 (enExample) | ||
| JP6488003B2 (ja) | 安定なモンテルカスト溶液 | |
| RU2488384C2 (ru) | Композиции для лечения неопластических заболеваний | |
| EP2911685A2 (en) | Stable pharmaceutical composition of peginterferon alpha-2b | |
| CN101773478B (zh) | 一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法 | |
| JP6346945B2 (ja) | 安定な静脈内製剤 | |
| KR20170072355A (ko) | C형 간염에 대한 장기 작용 약학적 조성물 | |
| KR102631084B1 (ko) | 면역 반응 증강용 복합체 | |
| CN103340831B (zh) | 注射用更昔洛韦粉针剂 | |
| CN108186597A (zh) | 一种鲁比前列酮固体分散体及其制备方法 | |
| US20110118362A1 (en) | Polymers for cardiopulmonary therapies | |
| RU2018123711A (ru) | Композиции для внутривенного введения | |
| CN114206319B (zh) | 用于治疗hbv的药物组合物 | |
| CN103830173A (zh) | 匹多莫德干混悬剂的制备方法 | |
| JP2019507195A5 (enExample) | ||
| WO2026062564A1 (en) | Compositions and methods for initiating a mucosal immune response | |
| JP2009507850A5 (enExample) |